Novartis India Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis India Limited with three other
companies in this sector in India:
Marksans Pharma Limited
sales of 8.93 billion Indian Rupees [US$131.14 million]
of which 100%
was Bulk Drugs Division),
Claris Lifesciences Ltd
(7.54 billion Indian Rupees [US$110.72 million]
Orchid Pharma Ltd
(8.73 billion Indian Rupees [US$128.22 million]
Novartis India Limited reported sales of 8.08 billion Indian Rupees (US$118.66 million)
March of 2016.
decrease of 7.4%
versus 2015, when the company's sales were 8.73 billion Indian Rupees.
Contributing to the drop in overall sales was the 70.0% decline
in Otc, from 1.29 billion Indian Rupees to 388.40 million Indian Rupees.
There were also decreases in sales in
Animal Health (down 19.1% to 774.30 million Indian Rupees)
Generics (down 19.9% to 388.10 million Indian Rupees)
However, these declines were partially offset by the increase in sales of
Pharmaceuticals (up 8.9% to 6.53 billion Indian Rupees)